Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

Rapamycin in cancer treatment (Qualy #61) — Whalespan

Content›Video›Rapamycin in cancer treatmen…

Rapamycin in cancer treatment (Qualy #61)

Peter Attia10m · 2020-02-14

Claims Made

20

Claims Supported

11

Support Rate

55%

Support rate

11 of 20 claims supported

11 supported9 partial / not

Claims from this content

17

✓Well SupportedEncapsulated rapamycin was effective in extending lifespan in both late middle-aged and younger mice.✓Well SupportedFemale mice may be more sensitive to rapamycin than male mice.✓Well SupportedRapamycin administered to 20-month-old mice significantly extends longevity, even when initiated late in life.✓Well SupportedDecline in immune function drives age-related cancer incidence and is more controllable than mutation accumulation.◐Partially Supported

More from Peter Attia

Peter Attia on Zone 2 Cardio

Peter Attia on Rapamycin (with Matt Kaeberlein)

Attia walks back the clinic protocol: too aggressive for healthy adults

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

At doses three times higher than the original ITP study, the lifespan benefit gap between male and female mice in rapamycin studies has significantly closed.

✓Well SupportedRapamycin and rapalogs may enhance immunity, leading to reduced infection and potentially reduced cancer.

◐Partially SupportedRapamycin treatment, by inhibiting mTOR, was predicted to accelerate muscle loss and induce sarcopenia in aging animals.

◐Partially SupportedRapamycin's effects on the immune system can be beneficial or detrimental for cancer, depending on dose.

◐Partially SupportedIn a study where 30-40% of vehicle-treated mice had non-hematopoietic cancers, none of the rapamycin-treated mice had them.

✕Not SupportedRapamycin is unlikely to cure existing cancer or modulate cancer incidence by affecting mutational frequencies.

✕Not SupportedHigh doses of rapamycin in animals may promote immune cancers.

✕Not SupportedHigh doses of rapamycin that inhibit immune function could promote cancer.

◐Partially SupportedRapamycin may potentially enhance the efficacy of cancer immunotherapies at very high doses.

◐Partially SupportedRapamycin may be unsuccessful as a chemotherapeutic agent for established cancers if they evolve to bypass the mTOR pathway inhibition.

◐Partially SupportedRapamycin may enhance cancer therapies in the elderly by improving immune function.

◐Partially SupportedA functioning immune system can clear mutations before they become problematic, suggesting immune surveillance is a key factor in preventing cancer.

◐Partially SupportedHigh-dose rapamycin (3 months) in animals was associated with aggressive hematological cancers.